Indeed, a study in NSCLC non-responders to immune checkpoint inhibitors (ICIs) identified an immune signature characterized by increased transcriptional activity in the NF-kB and STAT3 pathways, along with a higher level of CD4+ regulatory T cells, resident memory T cells, and TH17 cells [171]. Here, CD4 is linked to non-small cell lung carcinoma.